COTA, Inc. Expands Oncology Real-World Data Research & Consulting Services to Accelerate Safe, Effective Drug Development

COTA’s expanded services will provide even more support to organizations conducting research, like Bristol Myers Squibb, the US Food and Drug Administration, and Miami Cancer Institute. From protocol advisory and development to analytic and algorithmic support and publications, COTA’s expert guidance is a valuable asset for those looking to make advances in oncology research.

Baptist Health Miami Cancer Institute expands partnership with COTA.

Miami Cancer Institute has recently utilized COTA’s analysis of RWE to change its testing policy for breast cancer gene mutations. With the new technology, the institute has decided to test every patient diagnosed with the condition. Not only will this help with early detection, but it will also allow for more personalized treatment plans.

Key Takeaways from ASH 2022: Real-World Data Gets Down to Business

The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.

Are Pharma Companies Ready to Harness the Promises of Real-World Data?

Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.

The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting

COTA is honored to have contributed to three abstracts accepted for poster presentation at the American Society of Hematology’s 64th Annual Meeting, which cover a range of hematologic cancers. These studies focus on patient- and clinician-reported performance status in Multiple Myeloma, and real-world treatment patterns among patients with newly diagnosed Acute Myeloid Leukemia in the US.

COTA and Google Partner to Use Natural Language Processing to Harness Unstructured Data

We are excited to announce our partnership with Google Cloud to use their Natural Language Processing (NLP) technology to help us better understand the unstructured data in cancer patients’ medical records.

This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.